Abstract:N-formyl peptide receptors (FPR1, FPR2 and FPR3) are involved in innate immunity, inflammation and cancer. FPR expression, initially described in immune cells, was later observed in non-hematopoietic cell populations and tissues. Several studies suggested a role for FPRs in the progression of various tumor histotypes, including gastric cancer (GC), for which a positive association with a specific FPR1 polymorphism has recently been described. We previously showed that FPRs are expressed on gastric epithelium and are required for wound repair and restitution of barrier integrity. Here we assess the role of FPRs in GC. We characterized the functions of FPRs in GC epithelial cells (MKN28, AGS and MKN45) cultured in vitro by assessing migration, proliferation, resistance to apoptosis and activation of the epithelial-to-mesenchymal transition. Activation of each FPR induced the epithelial-to-mesenchymal transition, proliferation, resistance to apoptosis and migration of GC cells in culture. Blocking compounds or RNA interference of each FPR reverted these effects. We also defined the in vivo tumorigenic potential of GC epithelial cells silenced for FPRs by xenograft experiments in immunocompromised mice. Interestingly, FPR1 silencing in GC cells (shFPR1) significantly enhanced xenograft growth with respect to shCTR, shFPR2 and shFPR3 xenografts, because of augmented vessel density and cell proliferation. Accordingly, HIF-1α and VEGF mRNA levels were higher in shFPR1 xenografts than in controls. Moreover, the in vitro production of proangiogenic factors in response to FPR2/3 agonists (WKYMVm, LL-37, uPA, uPAR84-95, AnxA1) or to other proinflammatory mediators (IL-1α) was higher in shFPR1 GC cells than in shCTR, shFPR2 and shFPR3 cells, suggesting that FPR1 functions as an inhibitor of CG angiogenesis. Thus, we propose that FPR1 stimulation may represent a novel therapeutic approach to counteract tumor angiogenesis.

Identification of Oligomer Proanthocyanidins (F2) Isolated from Grape Seeds As a Formyl Peptide Receptor 1 Partial Agonist.

Oligomer Procyanidins (F2) Isolated From Grape Seeds Inhibits Tumor Angiogenesis And Cell Invasion By Targeting Hif-1 Alpha In Vitro

Oligomer Procyanidins (F2) Repress HIF-1α Expression in Human U87 Glioma Cells by Inhibiting the EGFR/ AKT/mTOR and MAPK/ERK1/2 Signaling Pathways in Vitro and in Vivo.

The G-protein Coupled Chemoattractant Receptor FPR2 Promotes Malignant Phenotype of Human Colon Cancer Cells.

Production of Angiogenic Factors by Human Glioblastoma Cells Following Activation of the G-Protein Coupled Formylpeptide Receptor Fpr

The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis

iTRAQ-Based Proteomic Analysis of Ginsenoside F2 on Human Gastric Carcinoma Cells SGC7901

Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists

Novel Small‐molecule Agonists of Human Formyl Peptide Receptors and Pharmacophore Models of their Recognition

The G-protein-coupled Formylpeptide Receptor FPR Confers a More Invasive Phenotype on Human Glioblastoma Cells

Ginsenoside F(2) Induces Apoptosis in Humor Gastric Carcinoma Cells Through Reactive Oxygen Species-Mitochondria Pathway and Modulation of ASK-1/JNK Signaling Cascade in Vitro and in Vivo.

Paeoniflorin Exerts Antitumor Effects by Inactivating S Phase Kinase-Associated Protein 2 in Glioma Cells

A novel FGF2 antagonist peptide P8 with potent antiproliferation activity

Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2

A Peptide Derivative Serves As A Fibroblast Growth Factor 2 Antagonist in Human Gastric Cancer

PP2 suppresses proliferation and migration of C6 Glioma and MDA-MB-231 cells by targeting both fibroblast growth factor receptor 1 and Src

Design, synthesis and evaluation of novel pyrimidinylaminothiophene derivatives as FGFR1 inhibitors against human glioblastoma multiforme

FTY720 Reduces Migration and Invasion of Human Glioblastoma Cell Lines Via Inhibiting the PI3K/AKT/mTOR/p70S6K Signaling Pathway

Antitumor Effect of a Short Peptide on P53-Null SKOV3 Ovarian Cancer Cells.

F3 Peptide-Functionalized PEG-PLA Nanoparticles Co-Administrated with Tlyp-1 Peptide for Anti-Glioma Drug Delivery

Regulation Of The Leucocyte Chemoattractant Receptor Fpr In Glioblastoma Cells By Cell Differentiation